title: Treatment with onvansertib, a specific PLK1 inhibitor, overcomes olaparib resistance in high-grade serous ovarian carcinoma patient-derived xenografts
design: Treatment with onvansertib, a specific PLK1 inhibitor, overcomes olaparib resistance in high-grade serous ovarian carcinoma patient-derived xenografts
library_construction_protocol: Tumors were transplanted in female Athymic Nude-Foxn1nu mice 6-weeks old obtained from Envigo Laboratories.  For the xenograft generation, patient-derived ovarian cancer ascites fluid was collect and transplanted intraperitoneally (i.p.) in the mice. When mice developed ascites, the ascetic fluid was collected, tumor cells pelleted and transplanted again i.p. in other mice. Stabilized PDXs were then used for in vivo activities. For RNAseq experiments, ovarian cancer ascites were collect from the mice, cells pelleted and snap-frozen. Before library preparation, RNA concentration was evaluated through Qubitâ„¢ RNA High Sensitivity Assay Kit (Invitrogen, Walthman, MA, USA) while RNA quality was established using 4200 Tapestation (Agilent Technologies, Santa Clara, CA, USA).  Protocol: miRNeasy Mini Kit. Following the TruSeq Stranded Total RNA protocol (Illumina, San Diego, CA, USA), at least 500 ng of RNA whose RIN value was between 7 and 9, were used for RNA sequencing. TruSeq Stranded Total RNA Sample Preparation Guide. Following the TruSeq Stranded Total RNA protocol (Illumina, San Diego, CA, USA), at least 500 ng of RNA whose RIN value was between 7 and 9, were used for RNA sequencing.